SPDR S&P Biotech (XBI) - Stock Price & Dividends
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A8707 • Health
The SPDR® S&P Biotech ETF (NYSE ARCA:XBI) aims to mirror the performance of the S&P Biotechnology Select Industry Index through a sampling approach. This fund typically invests almost all, with a minimum of 80%, of its assets in the index's securities, which encompass the biotechnology sector within the S&P Total Market Index.
The index, reflecting the biotechnology industry within the broader S&P TMI, provides investors with an opportunity to gain exposure to this specific segment of the market. By primarily investing in holdings from this index, the fund offers a chance to participate in the potential growth and performance of the biotechnology industry.
For further information on the SPDR® S&P Biotech ETF (NYSE ARCA:XBI), including specific details on its performance, holdings, fees, and more, you can visit the official website at http://www.spdrs.com. The fund is based in the United States, providing investors with access to the biotechnology sector within a diversified investment portfolio.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
XBI ETF Overview
Market Cap in USD | 7,911m |
Category | Health |
TER | 0.35% |
IPO / Inception | 2006-01-31 |
XBI ETF Ratings
Fundamental | - |
Dividend | 5.08 |
Growth 5y | -0.18 |
Rel. Performance vs Sector | -0.57 |
Analysts | - |
Fair Price Momentum | 85.73 USD |
Fair Price DCF | - |
XBI Dividends
Yield 12m | 0.02% |
Yield on Cost 5y | 0.02% |
Dividends CAGR 5y | 32.44% |
Payout Consistency | 51.2% |
XBI Growth Ratios
Growth 12m | 24.38% |
Growth Correlation 12m | 20% |
Growth Correlation 3m | 41% |
CAGR 5y | 1.02% |
Sharpe Ratio 12m | 0.67 |
Alpha vs SP500 12m | -10.18 |
Beta vs SP500 5y weekly | 1.09 |
ValueRay RSI | 43.37 |
Volatility GJR Garch 1y | 30.65% |
Price / SMA 50 | 1.86% |
Price / SMA 200 | 15.17% |
Current Volume | 12168.9k |
Average Volume 20d | 11747.3k |
External Links for XBI ETF
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 28, 2024, the stock is trading at USD 94.91 with a total of 12,168,850 shares traded.
Over the past week, the price has changed by -0.26%, over one month by -7.76%, over three months by +4.49% and over the past year by +26.66%.
According to ValueRays Forecast Model, XBI SPDR S&P Biotech will be worth about 95.8 in March 2025. The stock is currently trading at 94.91. This means that the stock has a potential upside of +0.93%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 95.8 | 0.93% |